目的　通过检测聚集素 (Clusterin)在前列腺正常、增生、癌变组织中的表达 ,探讨其与前列腺疾病发生发展的关系。　方法　采用免疫组织化学染色法检测 12例正常前列腺组织、15例良性前列腺增生组织 (BPH)、5 6例前列腺癌标本中Clusterin的表达水平。　结果　 3种组织中Clusterin的阳性及弱阳性表达率为 81% (67/83 ) ,其中前列腺正常、增生、癌组织中阳性及弱阳性表达率分别为17% (2 /12 )、73 % (11/15 )、96% (5 4/5 6)。前列腺癌组织中Clusterin表达水平明显高于前列腺正常 (t=8 82 ,P <0 0 1)及增生 (t =7 63 ,P <0 0 1)组织 ,且在癌组织中与肿瘤病理分级 (r =0 64 9,P <0 0 1)、临床分期 (r=0 60 9,P <0 0 1)呈正相关。　结论　Clusterin可能通过抗凋亡机制在前列腺癌的生物特性中发挥着重要的作用 Objective To detect the expression of Clusterin in normal prostatic hyperplasia and cancerous tissues and to explore its relationship with the occurrence and development of prostatic diseases. Methods Immunohistochemical staining was used to detect the expression of Clusterin in 12 cases of normal prostate tissue, 15 cases of benign prostatic hyperplasia (BPH) and 56 cases of prostate cancer. Results The positive and weak expression rates of Clusterin in the three tissues were 81% (67/83). The positive and weak positive rates of Clusterin were 17% (2/12) and 73% 11/15), 96% (54/5/5). The expression of Clusterin in prostate cancer was significantly higher than that in normal prostate (t = 8 82, P <0.01) and hyperplasia (t = 7 63, P <0.01) There was a positive correlation between clinical stage (r = 0 60 9, P 0 01) and clinical stage (r = 0 64 9, P 0 01). Conclusion Clusterin may play an important role in the biological characteristics of prostate cancer through the anti-apoptotic mechanism